Twelve genetic mutations in clear-cell renal cell carcinoma may predict which patients will experience recurrence; they could also help personalize adjuvant treatment, researchers say.
A unique study in patients with renal cell carcinoma on tyrosine kinase inhibitors (TKIs) shows that taking a break from the drugs is feasible and cost-effective.
First-line nivolumab plus cabozantinib continues to show superiority to sunitinib in the treatment of patients with advanced advanced renal cell carcinoma (RCC).
A novel combination of high-dose abatacept, ruxolitinib, and mechanical ventilation markedly improved immunotherapy-induced myocarditis survival over current guideline-recommended treatment.
Radiolabeled 89Zr-DFO-girentuximab PET/CT can accurately and noninvasively identify clear cell renal carcinoma, with minimal toxicity, say researchers reporting results from the phase 3 ZIRCON trial.